97 related articles for article (PubMed ID: 15674414)
21. FLT3 inhibition as tailored therapy for acute myeloid leukemia.
Martinelli G; Piccaluga PP; Lo Coco F
Haematologica; 2003 Jan; 88(1):4-8. PubMed ID: 12551818
[No Abstract] [Full Text] [Related]
22. Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia.
Scholl S; Krause C; Loncarevic IF; Müller R; Kunert C; Wedding U; Sayer HG; Clement JH; Höffken K
J Lab Clin Med; 2005 Jun; 145(6):295-304. PubMed ID: 15976757
[TBL] [Abstract][Full Text] [Related]
23. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
[TBL] [Abstract][Full Text] [Related]
24. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
Callens C; Chevret S; Cayuela JM; Cassinat B; Raffoux E; de Botton S; Thomas X; Guerci A; Fegueux N; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Ferrand A; Sanz M; Chomienne C; Fenaux P; Dombret H;
Leukemia; 2005 Jul; 19(7):1153-60. PubMed ID: 15889156
[TBL] [Abstract][Full Text] [Related]
25. The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia.
Sulong S; Case M; Minto L; Wilkins B; Hall A; Irving J
Br J Haematol; 2005 Sep; 130(6):964-5. PubMed ID: 16156866
[No Abstract] [Full Text] [Related]
26. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).
Nanri T; Matsuno N; Kawakita T; Suzushima H; Kawano F; Mitsuya H; Asou N
Leukemia; 2005 Aug; 19(8):1361-6. PubMed ID: 15902284
[TBL] [Abstract][Full Text] [Related]
27. FLT3 mutations in myeloid sarcoma.
Ansari-Lari MA; Yang CF; Tinawi-Aljundi R; Cooper L; Long P; Allan RH; Borowitz MJ; Berg KD; Murphy KM
Br J Haematol; 2004 Sep; 126(6):785-91. PubMed ID: 15352981
[TBL] [Abstract][Full Text] [Related]
28. FLT3/ITD mutation was not detected in a large series of non-Hodgkin lymphomas.
Shiozawa E; Takimoto M; Adachi D; Ota H
Leuk Res; 2004 Sep; 28(9):997-8. PubMed ID: 15234579
[No Abstract] [Full Text] [Related]
29. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia.
Moreno I; Martín G; Bolufer P; Barragán E; Rueda E; Román J; Fernández P; León P; Mena A; Cervera J; Torres A; Sanz MA
Haematologica; 2003 Jan; 88(1):19-24. PubMed ID: 12551822
[TBL] [Abstract][Full Text] [Related]
30. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
[TBL] [Abstract][Full Text] [Related]
31. Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type.
Chen W; Jones D; Medeiros LJ; Luthra R; Lin P
Br J Haematol; 2005 Sep; 130(5):726-8. PubMed ID: 16115128
[TBL] [Abstract][Full Text] [Related]
32. [FLT3 mutation in patients with acute lymphoblastic leukemia and its clinical significance].
Zhao X; Tang KJ; Tian Z; Chen LP; Mi YC; Wang JX
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):522-6. PubMed ID: 19968062
[TBL] [Abstract][Full Text] [Related]
33. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
Komeno Y; Kurokawa M; Imai Y; Takeshita M; Matsumura T; Kubo K; Yoshino T; Nishiyama U; Kuwaki T; Kubo K; Osawa T; Ogawa S; Chiba S; Miwa A; Hirai H
Leukemia; 2005 Jun; 19(6):930-5. PubMed ID: 15815726
[TBL] [Abstract][Full Text] [Related]
34. Effects of Flt3 ligand and interleukin-7 on in vitro growth of acute lymphoblastic leukemia cells.
Eder M; Hemmati P; Kalina U; Ottman OG; Hoelzer D; Lyman SD; Ganser A
Exp Hematol; 1996 Feb; 24(2):371-7. PubMed ID: 8641368
[TBL] [Abstract][Full Text] [Related]
35. FLT3 mutations in acute myeloid leukemia cell lines.
Quentmeier H; Reinhardt J; Zaborski M; Drexler HG
Leukemia; 2003 Jan; 17(1):120-4. PubMed ID: 12529668
[TBL] [Abstract][Full Text] [Related]
36. PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia.
Yamamoto T; Isomura M; Xu Y; Liang J; Yagasaki H; Kamachi Y; Kudo K; Kiyoi H; Naoe T; Kojma S
Leuk Res; 2006 Sep; 30(9):1085-9. PubMed ID: 16533526
[TBL] [Abstract][Full Text] [Related]
37. No correlation between trisomy 13 and FLT3 duplication in acute myeloid leukemia.
Powell H; Curtis A; Bown N; Taylor P
Cancer Genet Cytogenet; 2005 Jan; 156(1):92-3. PubMed ID: 15588866
[No Abstract] [Full Text] [Related]
38. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
39. Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype.
Neben K; Schnittger S; Brors B; Tews B; Kokocinski F; Haferlach T; Müller J; Hahn M; Hiddemann W; Eils R; Lichter P; Schoch C
Oncogene; 2005 Feb; 24(9):1580-8. PubMed ID: 15674343
[TBL] [Abstract][Full Text] [Related]
40. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
Drexler HG
Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
